Blog
RSS FeedPosted by Michael Wonder on 19 Jun 2017
Emerging use of early health technology assessment in medical product development: a scoping review of the literature
20 June 2017 - Early health technology assessment is increasingly being used to support health economic evidence development during early stages ...
Posted by Michael Wonder on 15 Jun 2017
Fostering medical innovation: a plan for digital health devices
15 June 2017 - It is incumbent upon FDA to ensure that we have the right policies in place to promote ...
Posted by Michael Wonder on 06 Jun 2017
Workshop: addressing unmet needs of children with pulmonary arterial hypertension
6 June 2017 - The EMA, the United States FDA and Health Canada are co-organising a workshop to discuss the ...
Posted by Michael Wonder on 17 May 2017
How patients are changing clinical trials
17 May 2017 - In September, the FDA approved a controversial drug to treat Duchenne muscular dystrophy, a rare but deadly ...
Posted by Michael Wonder on 04 May 2017
The failure of solanezumab — How the FDA saved taxpayers billions
3 May 2017 - The failure of solanezumab offers a window into the U.S. drug regulatory system, particularly in the context ...
Posted by Michael Wonder on 04 Apr 2017
Evaluation of evidence of statistical support and corroboration of sub-group claims in randomised clinical trials
3 April 2017 - Many published randomised clinical trials make claims for subgroup differences. ...
Posted by Michael Wonder on 02 Apr 2017
The nominee to run America’s drug regulator is a sound choice
1 April 2017 - Scott Gottlieb is close to the pharma industry but knows its tactics. ...
Posted by Michael Wonder on 30 Mar 2017
FDA: helping small businesses get big results
30 March 2017 - It is well known that small business is vital to the success of the American economy. Less ...
Posted by Michael Wonder on 29 Mar 2017
Trump’s nominee to lead the FDA got paid millions by the health care industry
29 March 2017 - Dr. Scott Gottlieb, President Donald Trump's nominee to head the FDA, is a widely respected physician ...
Posted by Michael Wonder on 23 Mar 2017
An FDA program incentivising rare disease drugs will be investigated for abuses
23 March 2017 - In late 1982, Congress overwhelmingly passed the Orphan Drug Act, which was then signed into law ...
Posted by Michael Wonder on 04 Mar 2017
GAO: drug makers want more clarity on antibiotic incentives
3 March 2017 - Despite some improvements, drug makers say the US FDA has not fully clarified its expectations for ...
Posted by Michael Wonder on 03 Mar 2017
Trump vows to 'slash restraints' on drug development for FDA
1 March 2017 - President Donald Trump used his first address to a joint session of Congress on Tuesday to, ...
Posted by Michael Wonder on 07 Feb 2017
Privatised pharmaceutical innovation vs access to essential medicines: a global framework for equitable sharing of benefits
7 February 2017 - The effect of the current privatized model of pharmaceutical innovation on the development and affordability of lifesaving ...
Posted by Michael Wonder on 03 Feb 2017
U.S. House panel to take up bill to spur generic drug development
2 February 2017 - A U.S. House of Representatives subcommittee will take up bipartisan legislation next week to foster generic ...
Posted by Michael Wonder on 02 Feb 2017
Drug development challenges for small biopharmaceutical companies
1 February 2017 - Small biopharmaceutical companies are becoming increasingly important as drivers of innovation in drug development. ...